To study the short-term effect of intravitreal injection of bevacizumab in the treatment of macular edema secondary to retinal macroaneurysm.

Eight eyes of 9 patients who underwent consecutive intravitreal bevacizumab injections for macular edema secondary to retinal macroaneurysm were prospectively evaluated. Complete eye examination including the best corrected visual acuity (BCVA), fundus examination and optical coherence tomography (OCT) were performed at baseline and follow-up visits at 2, 4 and 6 months.

The mean age was 73.6 ± 6.9 years, and the mean study period was 7.3 ± 2.6 months. At the final visit, BCVA improved from log MAR 1.92 ± 0.67 to log MAR 0.87 ± 0.57. The mean central macular thickness on OCT image decreased from 388 ± 168 µm at the initial visit to 200 ± 39 µm at the final visit. Three eyes without subretinal hemorrhage presented better visual outcome than eyes with subretinal hemorrhage. All eyes showed some decrease in angiographic leakage. No adverse side effects were observed following the injections.

Intravitreal bevacizumab injection can be used as a selective alternative treatment modality for macular edema secondary to retinal macroaneurysm.